HLS Historical Cash Flow
| HLS Stock | CAD 3.52 0.04 1.12% |
Analysis of HLS Therapeutics cash flow over time is an excellent tool to project HLS Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 15.7 M or Depreciation of 33.5 M as it is a great indicator of HLS Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining HLS Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether HLS Therapeutics is a good buy for the upcoming year.
HLS |
About HLS Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in HLS balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which HLS's non-liquid assets can be easily converted into cash.
HLS Therapeutics Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Capital Expenditures
Capital Expenditures are funds used by HLS Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of HLS Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Change To Inventory
The increase or decrease in the amount of inventory a company has over a certain period.Most accounts from HLS Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into HLS Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HLS Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, HLS Therapeutics' Change To Liabilities is very stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Capital Expenditures | 4.5M | 10.1M | 189K | 179.6K | Dividends Paid | 5.1M | 5.0M | 2.4M | 3.9M |
HLS Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
HLS Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
HLS Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 36.1M | (26.5M) | 567K | (456K) | 1.2M | 658.6K | |
| Free Cash Flow | 23.8M | (35.3M) | 11.9M | 6.8M | 15.6M | 16.4M | |
| Begin Period Cash Flow | 10.9M | 47.1M | 20.6M | 21.2M | 20.7M | 15.7M | |
| Other Cashflows From Financing Activities | (3.6M) | 21.0M | 4.9M | 9.5M | (1.4M) | (1.3M) | |
| Depreciation | 32.5M | 33.2M | 30.3M | 34.4M | 31.9M | 33.5M | |
| Other Non Cash Items | 10.4M | (894K) | (1.2M) | 1.5M | 7.6M | 8.0M | |
| Dividends Paid | 4.3M | 4.7M | 5.1M | 5.0M | 2.4M | 3.9M | |
| Capital Expenditures | 2.6M | 44.7M | 4.5M | 10.1M | 189K | 179.6K | |
| Total Cash From Operating Activities | 26.4M | 9.3M | 16.4M | 16.9M | 15.8M | 13.0M | |
| Net Income | (19.6M) | (15.3M) | (13.1M) | (23.6M) | (27.5M) | (26.2M) | |
| Total Cash From Financing Activities | 23.9M | 9.6M | (11.4M) | (6.9M) | (14.6M) | (13.9M) | |
| End Period Cash Flow | 47.1M | 20.6M | 21.2M | 20.7M | 22.0M | 16.6M | |
| Change To Inventory | (501K) | (8.1M) | 1.8M | (622K) | (661K) | (694.1K) | |
| Change In Working Capital | 1.5M | (7.7M) | (3.0M) | 1.5M | 5.0M | 5.3M | |
| Stock Based Compensation | 3.8M | 2.5M | 2.4M | 2.9M | (538K) | (511.1K) | |
| Sale Purchase Of Stock | 51K | 1.6M | (47K) | (998K) | (1.6M) | (1.6M) | |
| Change To Account Receivables | 6.1M | 1.5M | 1.0M | (71K) | 629K | 660.5K | |
| Net Borrowings | (5.5M) | 13.3M | (11.1M) | (441K) | (396.9K) | (377.1K) | |
| Total Cashflows From Investing Activities | (15.4M) | (44.7M) | (4.5M) | (10.1M) | (9.1M) | (9.6M) | |
| Change To Operating Activities | (2.0M) | (1.2M) | (1.7M) | (707K) | (636.3K) | (604.5K) | |
| Other Cashflows From Investing Activities | (12.8M) | (12.1M) | (3.8M) | (10M) | (9M) | (9.5M) | |
| Change To Netincome | 11.9M | (846K) | 2.3M | 4.6M | 4.1M | 3.9M | |
| Change To Liabilities | (2.0M) | (70K) | (3.6M) | 3.2M | 2.9M | 3.1M | |
| Investments | (15.4M) | (44.7M) | (4.5M) | (10.1M) | (189K) | (198.5K) |
Pair Trading with HLS Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLS Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLS Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against HLS Stock
The ability to find closely correlated positions to HLS Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLS Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLS Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLS Therapeutics to buy it.
The correlation of HLS Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLS Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLS Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLS Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in HLS Stock
The Cash Flow Statement is a financial statement that shows how changes in HLS balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which HLS's non-liquid assets can be easily converted into cash.